Novartis’s kinase inhibitor Piqray makes its way into Latin America



The National Health Surveillance Agency (ANVISA) this week granted Brazil market clearance to Switzerland-based Novartis’s oncology treatment Piqray (alpelisib), as GBI analysis reveals. The oral drug is developed to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. However, the agency is yet to publish indication details.

Some tumors can originate from unregulated activation of the phosphatidylinositol-3-kinase (PI3K) signaling pathway due to gain-of-function mutations in its gene. Piqray inhibits PI3K activity to prevent phosphorylation of its downstream targets, resulting in reduced tumor growth.

GBI analysis shows that ANVISA’s is the first approval obtained by Piqray in Latin America.

Reference:

Related news
Chinese biotech Innovent Biologics Inc., (HKEX.01801) announced first patient dosing in the ORIENT-31 Phase III clinical study, which is trying out a combination of two monoclonal antibodies (mAbs) plus chemotherapy in patients with epidermal growth factor (EGFR)-mutated non-squamous non-small cell lung cancer.
  • 1564023977047
  • China
  • Drug
Novartis’s dabrafenib and trametinib, Innovent Bio’s adalimumab biosimilar, Mundipharma Pharma’s pralatrexate, and Roche’s pertuzumab have been granted priority review and approval status by the Center for Evaluation (CDE) of National Medical Products Administration (NMPA), as gleaned by GBI.
China-based Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) announced a technology transfer and partnership agreement has been signed with compatriot firm Risen Pharmaceutical Co., Ltd (300105.SSE), conferring 50% of rights to two novel drug candidates.
Shenzhen’s municipal Human Resources and Social Security bureau released a shortlist of 10 drug therapies that could potentially gain local reimbursement coverage under the city’s Critical Disease Insurance (CDI) scheme.
Shandong's provincial Human Resources and Social Security bureau has opened up price negotiations in relation to 18 drugs with manufacturers and suppliers in return for Critical Disease Insurance (CDI) listings.
Recent news
A study carried out by investigators at Brazil’s Oswaldo Cruz Foundation (Fiocruz) estimated the coping costs for the caretakers of minors with one of three selected rare diseases.
Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) this week ruled that all medical products that contain active pharmaceutical ingredients (APIs) that require bioequivalence tests must submit applications for these studies within 180 days.
Austria-based Themis is set to carry out a Phase III clinical trial (CT) on its chikungunya vaccine candidate.
  • 1568979876836
  • Mexico,Colombia,Guatemala,Dominican Republic,Chile,Puerto Rico ,Nicaragua,Guyana,Brazil,Cuba,Belize,Argentina,Paraguay,Ecuador ,Costa Rica,Peru,El Salvador,Panama,Haiti,Uruguay,Venezuela,Bolivia ,Honduras
  • Drug, Company
China’s leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc., (NASDAQ: CBPO) is once again being targeted by a consortium of investors in a potential USD 4.59 billion buyout deal that would take the firm private.
Suzhou-based biotech CStone Pharmaceuticals (HKEX.2616) announced that the GEMSTONE-101 cohort study for anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) CS1001 combined with cisplatin plus fluorouracil (CF) therapy in esophagus squamous cell carcinoma (ESCC) has yielded a 77.8% objective response rate (ORR) with good safety.
Shenzhen Chipscreen Biosciences Co., Ltd, (SH.688321) announced acceptance for review from the National Medical Products Administration (NMPA) in relation to a new drug application (NDA) filed for hypoglycemic drug chiglitazar (Bilessglu).
A draft law presented this week to Peru’s unicameral Congress by the New Peru (Nuevo Perú) minority party would force medics to prescribe generic medicines as a primary choice and originator drugs as a second alternative.
Analytics Snapshot


Analytics Snapshot